MYTELASE Drug Patent Profile
✉ Email this page to a colleague
When do Mytelase patents expire, and what generic alternatives are available?
Mytelase is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in MYTELASE is ambenonium chloride. Additional details are available on the ambenonium chloride profile page.
Summary for MYTELASE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 44 |
Patent Applications: | 318 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MYTELASE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for MYTELASE
US Patents and Regulatory Information for MYTELASE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | MYTELASE | ambenonium chloride | TABLET;ORAL | 010155-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |